Literature DB >> 27989984

Anterior Cervical Discectomy and Fusion: Comparison of Fusion, Dysphagia, and Complication Rates Between Recombinant Human Bone Morphogenetic Protein-2 and Beta-Tricalcium Phosphate.

Brendan P Lovasik1, Christopher M Holland2, Brian M Howard3, Griffin R Baum3, Gerald E Rodts4, Daniel Refai5.   

Abstract

INTRODUCTION: Anterior cervical discectomy and fusion (ACDF) is one of the most common spinal procedures performed. A direct comparison of the fusion and complication rates between recombinant human bone morphogenetic protein-2 (rhBMP2) and beta-tricalcium phosphate (bTCP) has not been reported.
METHODS: A retrospective study of 191 consecutive patients who underwent ACDF with polyetheretherketone plastic fusion spacers during a 2-year period with either rhBMP2 (n = 84, 46%) or bTCP (n = 107, 56%) was performed. Patients underwent 1- (35%), 2- (41%), 3- (20%), and 4- (4%) level operations. The primary outcome measure was mature arthrodesis, with secondary measures including clinical outcomes and complication occurrence. Fusion was graded on plain lateral radiographs, with median length of follow-up of 12 months.
RESULTS: Rates of cervical fusion were significantly greater for patients treated with rhBMP2 than bTCP at both 6 months (70% vs. 26%, P = 0.000) and 12 months (99% vs. 85%, P = 0.000). Postoperative dysphagia was reported in 35 patients (18%), with no difference in dysphagia incidence between rhBMP2 and bTCP (20% vs. 17%, P = 0.5); however, dysphagia was more severe in the rhBMP2 group, with greater rates of readmission and steroid use (both P < 0.05). A multivariable sensitivity analyses to control for patient characteristics and number of spinal fusion levels showed no differences in dysphagia rate between rhBMP2 and bTCP.
CONCLUSIONS: In our cohort, the rate of mature arthrodesis after ACDF was greater with rhBMP2 compared with bTCP with no increased incidence of postoperative dysphagia; however, dysphagia severity was greater in the rhBMP2 cohort.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anterior cervical fusion; Bone morphogenetic protein

Mesh:

Substances:

Year:  2016        PMID: 27989984     DOI: 10.1016/j.wneu.2016.10.088

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Exploratory meta-analysis on dose-related efficacy and complications of rhBMP-2 in anterior cervical discectomy and fusion: 1,539,021 cases from 2003 to 2017 studies.

Authors:  Ya-Dan Wen; Wei-Min Jiang; Hui-Lin Yang; Jin-Hui Shi
Journal:  J Orthop Translat       Date:  2020-02-18       Impact factor: 5.191

2.  Risk factors and preventative measures of early and persistent dysphagia after anterior cervical spine surgery: a systematic review.

Authors:  Jingwei Liu; Yong Hai; Nan Kang; Xiaolong Chen; Yangpu Zhang
Journal:  Eur Spine J       Date:  2017-10-07       Impact factor: 3.134

3.  Prospective clinical and radiographic evaluation of an allogeneic bone matrix containing stem cells (Trinity Evolution® Viable Cellular Bone Matrix) in patients undergoing two-level anterior cervical discectomy and fusion.

Authors:  Timothy A Peppers; Dennis E Bullard; Jed S Vanichkachorn; Scott K Stanley; Paul M Arnold; Erik I Waldorff; Rebekah Hahn; Brent L Atkinson; James T Ryaby; Raymond J Linovitz
Journal:  J Orthop Surg Res       Date:  2017-04-26       Impact factor: 2.359

4.  Effect of the Presence and Type of Plate Augmentation on Postoperative Dysphagia Among Adult Patients Undergoing Elective Anterior Cervical Discectomy and Fusion for Spondylosis: A Randomized Trial.

Authors:  Tom J O'Donohoe; Lisa Mililli; Alison Magee; Christopher Thien; Yi Yuen Wang
Journal:  Neurospine       Date:  2020-03-31

5.  Comparison of Anterior Cervical Discectomy and Fusion with Cervical Laminectomy and Fusion in the Treatment of 4-Level Cervical Spondylotic Myelopathy.

Authors:  Xian-Zheng Wang; Huanan Liu; Jia-Qi Li; Yapeng Sun; Fei Zhang; Lei Guo; Peng Zhang; Chen-Hao Dou; Wei Zhang
Journal:  Orthop Surg       Date:  2021-12-13       Impact factor: 2.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.